Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Biomarker and possible therapeutic target for a variety of neurodegenerative diseases More
Propargylamine derivatives are used to treat Parkinson. Our novel derivatives inhibit monoamine oxidases (reducing oxidative stress) and cholinesterases, with higher efficiency than current drugs. They could relieve symptoms and prevent neurodegeneration More
Related Reports
Market Research Reports provided by reports.iptechex.com
Sep 2010 - 137 pages - $3,835
Sep 2011 - 80 pages - $3,500
Nov 2010 - 144 pages - $1,495
Oct 2011 - 145 pages - $3,500
Nov 2010 - 35 pages - $2,000
Feb 2011 - 69 pages - $500
Sep 2011 - 122 pages - $500
Sep 2011 - 31 pages - $500
Jun 2011 - 113 pages - $3,835
Jan 2007 - 236 pages - $2,250
Your selection
Browse By
- Industry sector
- Animal health
- Biotechnology
- Diagnostic
- Drug delivery
- Drug discovery
- Medical device
- Pharmaceutical
- Research tools
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us